Monte Rosa Therapeutics, Inc. (GLUE) Stock
5 of the hedge funds AlphaScala tracks reported GLUE in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $38.57M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own GLUE?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 1.59M | $38.57M | +11% |
| Duquesne Family Office Stanley Druckenmiller | 298K | $7.20M | NEW |
| D.E. Shaw David Shaw | 172K | $4.16M | +159% |
| Citadel Ken Griffin | 164K | $3.96M | -36% |
| Renaissance Technologies Jim Simons (founder) | 103K | $2.48M | -73% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Monte Rosa Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 5, 26 | Bowen Matthew | Principal Accounting Officer | SELL | 13 | $137 |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →GLUE price chart
Powered by TradingViewWhat does Monte Rosa Therapeutics, Inc. do?
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degraders (MGDs), a class of small molecule drugs that harness the body's natural protein destruction mechanisms to selectively eliminate therapeutically relevant proteins. The company employs its proprietary Quantitative and Engineered Elimination of Neosubstrates (QuEEN) platform, which integrates artificial intelligence and experimental tools to enable target-centric discovery and rational design of MGD product candidates. Key pipeline assets include MRT-2359, an orally bioavailable MGD targeting the GSPT1 protein for potential treatment of MYC-driven tumors such as metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Additional candidates like MRT-6160 and MRT-8102 address needs in oncology and autoimmune diseases. Monte Rosa Therapeutics, Inc. operates within the biotechnology and medical research sector, advancing novel therapeutic modalities to tackle serious diseases through precision protein degradation.